Does Blue Cross Blue Shield Cover Saxenda? What Your Plan Says in 2026 (and the 2027 Catch)

Some plans do, with prior approval. Other Blue Cross Blue Shield plans cover the weight-management generic (liraglutide) instead of brand Saxenda, or exclude weight-loss drugs entirely. Your exact benefit and drug list decide. Brand Saxenda's last shipments to wholesalers are planned for late January 2027.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

So "Do I have Blue Cross?" isn't the real question. The real questions are: does your plan cover weight-loss drugs, does it want the brand or the generic, and what's your plan for next year? The table below answers the first two for selected Blue plans. The checklist after it handles the third.

RX Index Decision Verdict: If your Blue plan covers weight-loss drugs, ask about generic liraglutide for weight management first, and plan ahead for the end of brand shipments.

• Best for: FEP Blue members, and members of employer plans that still include weight-loss drugs.
• Not ideal for: Expecting a new prescriber to overcome an excluded weight-loss drug benefit. Saxenda has no other FDA-approved use to fall back on.
• The factor that matters most: Whether your exact plan has a weight-loss drug benefit at all.

Does Blue Cross Blue Shield cover Saxenda? The plan-by-plan answer

Blue Cross Blue Shield isn't one insurer. It's a network of independent Blue Cross and Blue Shield companies, and often your employer decides whether weight-loss drugs are covered. The FEP drug lists below require prior authorization and treat brand Saxenda and generic liraglutide as two different entries.

Prior authorization (PA) is a permission slip from your plan. Your prescriber asks first and the plan reviews your records; payment still depends on your benefits and the pharmacy claim. A tier is a price group, not a dollar amount.

Here's what each plan's own documents say. We read every source listed in the right-hand column.

The FEP rows describe the FEHB traditional pharmacy benefit, not the Medicare Prescription Drug Program. The current lists took effect October 1, 2026; the published 2027 lists take effect January 1, 2027. Their placements do not establish your own approval or confirm unchanged 2027 PA rules.

The Illinois and Texas Annual-list exceptions name Basic Annual, Multi-Tier Basic Annual, Enhanced Annual, Multi-Tier Enhanced Annual and Performance Annual. In Vermont, fully insured large-group clients and Blue Edge Classic clients can choose to keep weight-loss GLP-1 coverage; the Vermont row is not a company-wide exclusion.

Blue Cross's Montana, New Mexico and Oklahoma plans published similar April 2026 notices naming Saxenda and noting a generic equivalent. Montana fully insured members have these revisions deferred until on or after January 1, 2027. Check your own list.

One honest limit: no public document can tell you whether you will be approved or what you will pay. Your plan, your prescriber and your pharmacy settle that. Start with one phone call. We've written the script for you below.

Which treatment path makes sense depends on more than your Blue card. It depends on your state, your exact drug list, whether you want an FDA-approved medicine or are considering compounded treatment, a shot or a pill, and your budget. Once you know your plan's rule, answer a few quick questions in The RX Index's Find My GLP-1 Path tool to see the GLP-1 paths and providers that fit your goals, budget, insurance and situation. It's free, takes about 2 minutes, and needs no signup. It doesn't check your insurance coverage. That part is the call below.

See which GLP-1 path fits your Blue plan

Brand Saxenda or generic liraglutide: which one does your plan pay for?

Generic liraglutide for weight management has the same active ingredient, strength and FDA-approved use as Saxenda. The FDA approved the first one on August 27, 2025; Teva announced its launch the next day. Cipla announced another launch in February 2026. Your plan can cover the brand, the generic, both, or neither, and it can put them on different tiers.

Think of the store brand and the name brand sitting next to each other on a shelf. Same active ingredient. Different price tag. Your plan picks which one it pays for.

On FEP Blue's traditional benefit, that difference is big. The generic is Tier 1, a flat copay. The brand is Tier 3, a percentage of the plan's allowed price, or not on the normal list on Focus. The Illinois and Texas notices described above dropped the brand for the affected members and named a generic alternative; check whether your benefit covers it.

These products share the ingredient name liraglutide, and mixing them up can cause a confusing denial:

Your prescriber should report your real diagnosis and request the appropriate product. A diabetes-only coverage rule doesn't establish weight-loss coverage; choosing the wrong liraglutide entry can cause a denial.

One more detail. Prime's August 2026 market update reports that Teva stopped marketing its weight-management generic in May 2026. That report doesn't tell you what your pharmacy has now. Ask which weight-management product it can fill.

Already taking Saxenda? The January 2027 shipment change

Novo Nordisk says it is discontinuing Saxenda, with last shipments to wholesalers in late January 2027. The company says this is a business decision, not a safety or quality problem. Pharmacies can keep filling prescriptions while their supply lasts, but nobody can tell you exactly when your local pharmacy will run out.

Say you're on brand Saxenda through an employer Blue plan and doing well on it. Here's how to plan ahead:

1. Ask your pharmacy how much brand Saxenda it expects to keep getting.
2. Ask your plan: "Is generic liraglutide for weight management covered? What tier? Does my Saxenda approval cover it, or do I need a new one?" An approval can be tied to the exact product, so don't assume yours carries over.
3. Talk with your prescriber about what comes next for you. That could be the generic, another covered medicine, or something else. The choice is theirs and yours to make together, not a website's.
4. Write down two dates: when your approval ends and when your plan renews. They're different clocks.
5. Price a backup before you need one. The cost section below shows real numbers.

If you're switching anyway, our Saxenda alternatives guide compares the options side by side.

How to check your own Saxenda coverage

Check Saxenda and generic liraglutide as two separate entries, using the pharmacy benefit tied to your own plan. Write down four things: whether your plan covers weight-loss drugs at all, what the drug list says, what approval is needed, and what you'd pay.

Your drug list (also called a formulary) is your plan's list of covered drugs. Log in to your member portal or call the pharmacy number on your card. Don't guess your plan from the state you live in. Use the company and pharmacy-benefit details on your card.

Copy this and read it on the call:

"I'm checking Saxenda under my current pharmacy benefit. Is brand Saxenda covered? Is liraglutide for weight management covered as a separate drug? Does my plan exclude weight-loss drugs? Which prior authorization policy applies, and can you send it to me? What would I pay at my pharmacy for a 30-day supply? If the answer is no, is that because the benefit is excluded, the drug isn't on the list, or a request was denied? Please give me a reference number for this call."

Then fill this in. Keep it private.

If you're on FEP Blue, you can also look yourself up in FEP's prescription drug cost tool. FEP says 2027 prices go live there on November 6, 2026.

What "not covered" really means

A "no" can mean three very different things: your plan excludes weight-loss drugs, your plan doesn't list the brand, or a prior authorization request was denied. Each one has a different next step, so get the exact reason in writing before you do anything else.

Here's the part most pages skip. Saxenda has only one FDA-approved use: weight management. Wegovy tablets and injection also reduce major cardiovascular risks in adults with established cardiovascular disease and overweight or obesity. The injection additionally has an accelerated approval for adults with noncirrhotic MASH, a form of fatty liver disease, and moderate-to-advanced liver scarring (F2–F3). Zepbound also treats moderate-to-severe obstructive sleep apnea in adults with obesity. Some Blue plans cover those uses under separate rules; others, including the affected Massachusetts plans, exclude these drugs even for those uses unless an employer rider applies. Saxenda has no other use to fall back on. A routine PA cannot create an excluded benefit, but you can ask whether the exclusion was applied correctly and what review rights apply.

That doesn't mean you're stuck. Say you're 46, on a Blue plan through work, and your letter says "benefit exclusion." Resending the same request won't change the plan's rules. But one email to HR might: "Does our plan offer a weight-loss drug rider or option at renewal? When is the next benefit decision?" You can also ask the plan whether the exclusion was applied correctly to you.

If the denial concerns missing records or clinical criteria, gather these before you appeal: the denial letter, the exact reason, the policy it cites, your prescriber's records that answer that reason, and the deadline. Our guides on how to appeal a GLP-1 denial, how a formulary exception works, and the difference between an exclusion and a prior authorization walk through each step. There's also a ready-to-edit appeal letter template.

If a refill is rejected and you're worried about a gap in treatment, call the prescriber who manages your care. Don't stop, restart or change doses on your own.

What Blue Cross needs to approve Saxenda

There's no single Blue Cross checklist. The two policies below ask for a qualifying BMI, records of a weight-management program or lifestyle changes, and no other GLP-1 at the same time. Approval periods and renewal rules differ. Ask which policy applies to your request.

BMI (body mass index) is a number based on your height and weight. Here are the two Blue policies we read in full, next to what the FDA label says:

Ask your prescriber which documented treatment baseline your plan will use. Keep that number on file, especially if you changed medicines or plans. These are policy examples, not complete approval checklists. The HCSC policy also checks whether this plan approved your earlier request; some requests need an initial review instead.

Check your weight-loss percentage before Saxenda renewal

Put in your documented baseline weight and your weight today. You'll see your percent lost and how it compares with the published numbers. Two weights can't show whether you've maintained a loss or met the other renewal rules. Your plan and your prescriber still make those calls.

Worked example (made up):

Say your documented baseline was 240 pounds and you weigh 228 pounds at week 16. You've lost 12 pounds. 12 ÷ 240 = 0.05, or 5%. That reaches the numeric 5% line FEP publishes and the 4% line in the cited HCSC policy; the other renewal requirements still apply.

The formula is: (baseline weight − current weight) ÷ baseline weight × 100. Use the same unit for both weights.

One safety note before anyone starts. Saxenda's label says not to use it if you or your family have had medullary thyroid carcinoma (MTC), if you have multiple endocrine neoplasia syndrome type 2 (MEN 2), or if you've had a serious allergic reaction to the product. It tells clinicians to stop treatment once a pregnancy is known. If you're under 18, pregnant or planning a pregnancy, have type 1 diabetes or a history of an eating disorder, or have been told a GLP-1 may not be safe for you, start with your own clinician before choosing any program.

What Saxenda costs with Blue Cross, and without it

There's no single Blue Cross price for Saxenda. What you pay depends on your tier, your deductible, whether you owe a copay (a flat dollar amount) or coinsurance (a percent of the plan's allowed price), and the pharmacy. NovoCare publishes a $1,349.02 list price; that isn't a pharmacy cash quote, and the old manufacturer savings offer has ended.

For FEP's FEHB traditional pharmacy benefit, these are the standard charges at a Preferred retail pharmacy for up to a 30-day supply, from FEP's prescription page. The figures appear in both the 2026 and 2027 benefits; Medicare-related pharmacy benefits can differ.

FEP Standard and Basic can also charge the difference between the brand and generic costs when generic substitution is available and the brand is requested. Their 2026 brochure and 2027 brochure say only the applicable tier charge applies when the prescriber specifies the brand as "dispense as written." Ask the pharmacy which rule applies to your prescription.

Here's how coinsurance works, using made-up numbers. Say you're on FEP Blue Standard and the Plan allowance for the prescribed fill of brand Saxenda is $1,000. The 50% coinsurance portion would be $500, before any applicable brand-versus-generic charge. The generic at Tier 1 would be a $7.50 copay under the benefit shown above. The $1,000 is invented to show the math. Ask your pharmacy to run your real claim.

Two more cost facts:

• Saxenda list price: $1,349.02, per NovoCare. The page doesn't state the package or supply size beside that figure. Get a pharmacy quote for your exact prescription; don't treat it as a monthly out-of-pocket price.
• Saxenda savings card: the old offer has ended. New enrollment closed June 30, 2023, and previously activated benefits expired December 31, 2023. If a website still offers you a current $25 Saxenda card, it's out of date.

If your plan won't pay: what other FDA-approved options really cost

If your plan won't cover Saxenda or its generic, the main question becomes cost. The True Monthly Cost is the whole receipt, not the sticker price: medicine plus required membership, visits, labs and delivery. The table below shows medicine-plus-membership subtotals, not a complete bill. These are FDA-approved brand-name options, not Saxenda, and your prescriber decides whether any of them fits you. Prices are from Ro's pricing page, checked October 22, 2026, with the manufacturer offer terms linked below. Ro says its cash prices match LillyDirect, NovoCare and TrumpRx.

The offer terms change the bill:

• Wegovy: Ro advertises a December 31, 2026 signup deadline for its $199 introductory offer. For the NovoCare Pharmacy offer, eligible new patients need prescriptions written and received by December 31, 2026 and shipped by January 31, 2027. A separate retail savings-card offer has its own fill/redemption deadline. Account signup alone doesn't establish eligibility for two discounted fills.
• Zepbound: To keep the $449 price at 7.5–15 mg, the purchase-offer terms require the refill purchase within 45 days of receiving the prior fill. Lilly lists regular medicine prices of $499 at 7.5 mg and $699 at 10–15 mg. Confirm Ro's price if the purchase offer does not apply.
• Foundayo: The manufacturer's terms limit the reduced 2.5 mg and 5.5 mg prices to December 31, 2026. Lilly lists regular prices for those doses of $199 and $299. Continued $299 pricing at 14.5/17.2 mg requires a refill purchase within 45 days of receiving the prior fill. Lilly lists $349 as the regular price for those higher doses; confirm Ro's price if the offer does not apply.

The injection supplies above last 28 days; the pills last 30 days. Ro membership has its own billing cycle. These sums don't predict your dose schedule or align every refill with a calendar-month charge. A new membership doesn't necessarily mean a starting-dose prescription.

What the table doesn't include: Ro's advertised 12-month plan is $74 a month, but you prepay $888 for the year. Ro's terms say membership renews automatically, must be canceled at least 48 hours before renewal, and isn't refundable once paid. If no medicine is ever prescribed, Ro says it refunds the onboarding purchase; that is not a refund guarantee after an insurance denial or an unfilled prescription.

Ro also charges $15 for each consult beyond 24 a year, and additional lab tests can be billed separately, per its terms of use. Ask about any supplies, delivery, taxes or other charges for your order; an unknown fee isn't $0. Dose changes are your prescriber's call, so your own cost depends on your plan of care.

If you already have a prescriber, buying eligible medicines through manufacturer pharmacy programs avoids a separate Ro membership fee; your own clinician's charges still count.

If you're an adult who has decided to compare brand-name options with a program that provides clinical visits and ongoing care, this is the straightforward place to compare. A prescription depends on clinical review. Medicare and Medicaid readers should start with the program-specific steps below.

Your next step if your plan won't pay for Saxenda

Start with the reason your plan won't pay. A brand-only problem, a missing approval and an excluded benefit lead to different next steps. And changing providers doesn't change what your plan covers.

Your plan covers a different medicine

Ask your prescriber whether the covered generic, or another medicine on your list, makes sense for you. Then check that drug's rules and price before you pay for anything new. Our guides cover Blue Cross and Wegovy, Blue Cross and Zepbound, Blue Cross and Foundayo, and Wegovy vs. Zepbound vs. Saxenda.

If you're looking at the Wegovy pen, Zepbound autoinjector pen or Ozempic pen, Ro's free insurance checker checks those products. It doesn't check Saxenda, the Wegovy pill or the Zepbound KwikPen.

Here's the honest trade-off with Ro. The membership is a separate cash cost from your medicine. If your own in-network doctor can write the prescription and send the paperwork, that may avoid a separate program fee; compare your visit and medication costs.

If you don't have that doctor, or your office won't handle prior authorization, Ro says its insurance team submits the paperwork and handles the back-and-forth for its supported insurance medicines: Wegovy pen, Zepbound autoinjector pen and Ozempic pen, according to its current insurance page. That isn't a promise of Saxenda insurance support.

For an adult with commercial or FEHB insurance considering one of those alternatives, Ro's published offer starts at $39 for the first month, then as low as $74 a month on an annual plan prepaid at $888, or $149 month to month. Medicine is billed separately, and paying for membership doesn't guarantee approval.

Your plan excludes weight-loss drugs entirely

Three options to ask about are a rider through your employer, a different plan at open enrollment, or paying cash for an FDA-approved option. Ask HR first. It costs one email. If the answer is no, compare cash paths using the table above. Your clinician can also discuss other covered weight-management care. Our guide to what to do when insurance won't cover weight-loss medicine goes deeper.

You may also see compounded GLP-1s advertised as cheaper. Compounded drugs are not FDA-approved, and the FDA doesn't review them for safety, effectiveness or quality before they reach patients (FDA). They're a separate path, covered in our guide to compounded GLP-1 status. This page sticks to FDA-approved options.

If cost is now the deciding factor, see which FDA-approved path fits your budget, insurance and preferences side by side before you spend anything.

Compare paths that fit your budget

If you have Medicare, Medicaid or FEP, or you're checking for your teen

• Blue Medicare plans: Standard Part D coverage excludes drugs when used for weight loss; enhanced plans may offer excluded drugs through supplemental benefits, so check your plan. The separate Medicare GLP-1 Bridge, which started July 1, 2026, covers Foundayo, Wegovy (shot or pill) and the Zepbound KwikPen for a $50 monthly copay for eligible beneficiaries who meet its clinical and authorization rules. It does not include Saxenda or liraglutide (Medicare.gov). See our guides to the Medicare GLP-1 Bridge and Blue Cross Medicare GLP-1 rules.
• Blue Medicaid plans: Your state's rules decide. Start with what GLP-1 Medicaid covers and the member number on your card.
• FEP Blue's FEHB traditional benefit: The generic is Tier 1 with PA on all three plans in 2026 and 2027. Open Season details are in does FEHB cover GLP-1 and GLP-1 providers that accept FEP Blue.
• Teens 12 to 17: Saxenda and its weight-management generic are approved for teens over 60 kg (about 132 pounds) with obesity. Plans use teen-specific criteria. Work with your child's clinician.

What we actually verified

Checked October 22, 2026:

• NovoCare's Saxenda page (discontinuation notice and ended savings offer) and list-price page
• Saxenda prescribing information, revised February 2026; the Wegovy and Zepbound labels for the other uses discussed above
• The FDA's first-generic approval entry, generic-drug requirements, and Teva's and Cipla's launch announcements
• FEP Blue's 2026 and published 2027 FEHB traditional drug lists for Standard, Basic and Focus; both years' benefit brochures; FEP's retail cost-share page; and FEP policy 5.99.030 (effective July 1, 2026)
• The HCSC weight management policy (effective June 15, 2026); members must confirm whether it applies to their plan
• The full April 2026 drug-list updates from Blue Cross of Illinois, Texas, Montana, New Mexico and Oklahoma; the North Dakota notice; the Michigan alert; Vermont's FAQ and provider newsletter; and Massachusetts' coverage update and fact sheet
• Medicare.gov's GLP-1 Bridge page and CMS's explanation of standard exclusions and supplemental benefits
• Prime Therapeutics' August 2026 GLP-1 update (its report on generic liraglutide makers)
• Ro's pricing, Saxenda, insurance, checker and terms pages, plus NovoCare's and Lilly's offer terms
• The FDA's compounding Q&A and HealthCare.gov's appeal-rights guidance

Provider-stated, not tested by us: Ro's statements that its insurance team handles prior authorization paperwork for its supported medicines and that its cash prices match the drugmakers' own pharmacies.

What we couldn't confirm: whether your approval carries over from brand to generic (that's plan-specific), your final pharmacy price, and how long any given pharmacy will have brand Saxenda after January 2027. We didn't check your member account, submit a claim or complete a paid checkout.

You can read how we evaluate in our methodology.

Frequently asked questions

Do I need type 2 diabetes for Blue Cross to cover Saxenda?

No. Saxenda is a weight-management medicine, so diabetes isn't required. If a liraglutide denial says you need diabetes, the request may have been for the diabetes product (Victoza or its generic) instead of the weight-management one. Ask your prescriber and pharmacist to confirm which product was submitted.

Why does my drug list say covered, but the pharmacy says no?

Being on the drug list isn't the same as being approved. The claim may need an approved prior authorization, or the approval may not match the exact product, quantity or pharmacy. Ask the pharmacy for the rejection reason, then call your plan with it.

Can my employer's Blue Cross plan exclude Saxenda?

Yes. Some employer plans, and some Blue companies for whole groups of plans, have dropped weight-loss drugs. A coworker's Blue Cross card may come with different benefits than yours. Ask HR what your current plan includes and whether a rider is offered at renewal.

Does Blue Cross cover generic liraglutide instead of Saxenda?

Some plans do. FEP Blue lists the weight-management generic at Tier 1 with PA on all three FEHB traditional plans. The Illinois and Texas notices above remove the brand for affected members and name a generic alternative; they don't confirm your personal benefit. Ask whether your Saxenda approval covers the generic or whether you need a new request.

Is Saxenda being discontinued?

Yes. Novo Nordisk says its last shipments of Saxenda to wholesalers are planned for late January 2027, and that it's a business decision, not a safety or quality issue. Pharmacies can fill prescriptions while their supply lasts. Talk with your prescriber about what comes next.

Does FEP Blue cover Saxenda?

Under FEP Blue's FEHB traditional pharmacy benefit, Standard and Basic list brand Saxenda at Tier 3 with prior approval. FEP Blue Focus doesn't list the brand. All three list the weight-management generic at Tier 1 with prior approval, in 2026 and on the 2027 lists.

What does Blue Cross require for Saxenda prior authorization?

It depends on your plan. FEP and the cited HCSC commercial policy both ask for a qualifying BMI, a weight management program or lifestyle changes, and no other GLP-1 at the same time. Get your own plan's written policy before your prescriber submits; the HCSC policy does not apply to every member in those five states.

How much weight do I need to lose to keep Saxenda coverage?

Under the cited FEP policy, adults need at least 5% loss from baseline, or to maintain that initial loss. The cited HCSC policy requires adults to achieve and maintain at least 4%, along with its other criteria. Separately, the FDA label asks prescribers to check weight at 16 weeks and stop if loss is under 4%; today's weight alone can't establish an earlier result.

Does Medicare cover Saxenda?

Standard Part D coverage excludes medicines used for weight loss, though an enhanced plan may offer separate supplemental benefits. The $50 Medicare GLP-1 Bridge covers specified alternatives for eligible beneficiaries, but not Saxenda or liraglutide. Check your plan's benefits rather than assuming every Blue Medicare plan is identical.

Is there a Saxenda savings card?

The old manufacturer offer has ended. New enrollment closed June 30, 2023, and previously activated benefits expired December 31, 2023. NovoCare's $1,349.02 list price is not a pharmacy cash quote or a verified monthly cost.

Can I appeal if Blue Cross won't cover Saxenda?

If your request was denied, you can appeal. Get the reason, fix what's missing with your prescriber, and follow the deadline in the letter. If your plan excludes weight-loss drugs entirely, an appeal usually can't add a benefit the plan doesn't have, but you can ask whether the exclusion was applied correctly.

Does Ro's free checker check Saxenda?

No. Ro's free insurance checker checks the Ozempic pen, Wegovy pen and Zepbound autoinjector pen. Ro's Saxenda page says it may prescribe Saxenda to appropriate adults, but its current insurance page names only those three pens for insurance support. Check Saxenda coverage through your own plan or pharmacy, and confirm the Saxenda service with Ro before paying.

Sources

Checked October 22, 2026. Dates in source titles below describe publication, revision or policy-effective dates.

1. NovoCare: Saxenda discontinuation notice and savings offer update
2. NovoCare: Saxenda list price
3. Saxenda prescribing information, revised February 2026
4. FEP Blue Standard FEHB traditional drug lists: October 1, 2026 and January 1, 2027
5. FEP Blue Basic FEHB traditional drug lists: October 1, 2026 and January 1, 2027
6. FEP Blue Focus FEHB traditional drug lists: October 1, 2026 and January 1, 2027
7. FEP Blue prescription drug coverage and cost shares
8. FEP policy 5.99.030, Saxenda and Wegovy, effective July 1, 2026
9. HCSC Weight Management Prior Authorization program summary, effective June 15, 2026
10. BCBS of Illinois pharmacy update, changes effective April 1, 2026 with listed deferrals
11. BCBS of Texas pharmacy update, changes effective April 1, 2026 with listed deferrals
12. BCBS of North Dakota: 2026 weight-loss drug changes, published August 7, 2025
13. BCBS of Michigan provider alert, September 27, 2024
14. BCBS of Vermont GLP-1 FAQs and October 2025 provider newsletter
15. BCBS of Massachusetts: GLP-1 medications for obesity coverage update and provider fact sheet
16. Medicare.gov: weight-loss drugs and the Medicare GLP-1 Bridge
17. Prime Therapeutics: GLP-1 pipeline update, August 2026
18. Ro: weight loss pricing
19. Ro: Saxenda
20. Ro: terms of use
21. FDA: Compounding and the FDA, questions and answers
22. FDA: 2025 First Generic Drug Approvals, liraglutide/Saxenda entry
23. FDA: Generic Drug Facts
24. Teva: approval and launch announcement, August 28, 2025
25. Cipla: generic Saxenda launch announcement, February 27, 2026
26. FEP Blue Standard and Basic FEHB brochures: 2026 and 2027, Section 5(f)
27. FEP Blue Focus FEHB brochures: 2026 and 2027, Section 5(f)
28. FEP drug-cost tool availability and MPDP distinction
29. April 2026 pharmacy updates: BCBS Montana, BCBS New Mexico and BCBS Oklahoma
30. Wegovy prescribing information
31. Zepbound prescribing information
32. CMS: Excluded Drug Reference File FAQs, December 2020, questions 1 and 6
33. Ro: insurance support and supported products
34. Ro: free GLP-1 insurance checker
35. NovoCare Pharmacy eligibility and offer terms
36. Lilly: Zepbound pricing and purchase-offer terms
37. Lilly: Foundayo pricing and purchase-offer terms
38. HealthCare.gov: How to appeal an insurance company decision